Opin vísindi

Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis

Show simple item record

dc.contributor.author Neumann, Bjoern
dc.contributor.author Foerster, Sarah
dc.contributor.author Zhao, Chao
dc.contributor.author Bodini, Benedetta
dc.contributor.author Reich, Daniel S.
dc.contributor.author Bergles, Dwight E.
dc.contributor.author Káradóttir, Ragnhildur Þóra
dc.contributor.author Lubetzki, Catherine
dc.contributor.author Lairson, Luke L.
dc.contributor.author Zalc, Bernard
dc.contributor.author Stankoff, Bruno
dc.contributor.author Franklin, Robin J.M.
dc.date.accessioned 2022-08-26T01:04:19Z
dc.date.available 2022-08-26T01:04:19Z
dc.date.issued 2020-05-07
dc.identifier.citation Neumann , B , Foerster , S , Zhao , C , Bodini , B , Reich , D S , Bergles , D E , Káradóttir , R Þ , Lubetzki , C , Lairson , L L , Zalc , B , Stankoff , B & Franklin , R J M 2020 , ' Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis ' , Cell Stem Cell , vol. 26 , no. 5 , pp. 617-619 . https://doi.org/10.1016/j.stem.2020.03.017
dc.identifier.issn 1934-5909
dc.identifier.other PURE: 43318775
dc.identifier.other PURE UUID: 7498963f-1ca4-4bac-8888-cc14294f2fac
dc.identifier.other Scopus: 85084118366
dc.identifier.uri https://hdl.handle.net/20.500.11815/3374
dc.description The authors acknowledge the following support: The UK Multiple Sclerosis Society (MS50 to R.T.K., C.Z., and R.J.M.F.), The Adelson Medical Research Foundation (D.S.R., D.E.B., and R.J.M.F.), Intramural Research Program of NINDS/NIH (D.S.R.), European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Program (771411 to R.T.K.), The Lister Institute (R.T.K.), and a core support grant from the Wellcome and MRC to the Wellcome-Medical Research Council Cambridge Stem Cell Institute (203151/Z/16/Z to R.T.K. and R.J.M.F.). Publisher Copyright: © 2020 Elsevier Inc.
dc.description.abstract Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.
dc.format.extent 3
dc.format.extent 617-619
dc.language.iso en
dc.relation info:eu-repo/grantAgreement/EC/H2020/771411
dc.relation.ispartofseries Cell Stem Cell; 26(5)
dc.rights info:eu-repo/semantics/openAccess
dc.subject MS sjúkdómur
dc.subject Molecular Medicine
dc.subject Genetics
dc.subject Cell Biology
dc.title Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.pmid 32386552
dc.identifier.doi https://doi.org/10.1016/j.stem.2020.03.017
dc.relation.url http://www.scopus.com/inward/record.url?scp=85084118366&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine

Files in this item

This item appears in the following Collection(s)

Show simple item record